Advances in the analysis of circulating-free DNA (cfDNA) obtained from the plasma fraction of peripheral whole blood are facilitating minimally invasive methods to monitor health and disease. As a potential tool for the detection of cancer-specific biomarkers, liquid biopsy has considerable diagnostic and prognostic applications and has demonstrated the utility of capturing solid tumor heterogeneity and relevant actionable mutations. This analytical validation characterizes The Oncomine™ Precision Assay’s detection of hotspot mutations (substitutions, insertions, deletions, and copy number variations [CNVs]) for liquid biopsy samples. Download this poster to explore the methods, results, and conclusions of this study.

Complete the form below to access this scientific poster.